Archives: Speakers

Kent Thoelke

As PRA’s Chief Scientific Officer, Mr Thoelke provides corporate oversight and strategy for Scientific & Medical Affairs, Pharmacovigilance & Patient Safety, Therapeutic Centers of Excellence, Real World Data, Patient Access & Experience, Digital Health & Virtual Trials, and their integration into operational delivery. Mr Thoelke is an industry pioneer in the application of mobile first strategies, which integrate clinical trials and provide access directly to patients in both virtual and hybrid-virtual models. He emphasizes leveraging real world data, social insights, and patient connectivity to advance global drug development.

Mimi Choon-Quinones

I am passionate about advocating for patients by improving healthcare policies, advancing medical knowledge, driving innovative digital solutions in the quest to increase medical access to treatments for patients. I feel it is one of my responsibilities to support every patient around the world who struggles to get access to medicines.

Stuart Coleman

Stuart Coleman is passionate about the opportunities for people to use technology, data and machines to learn new skills and shape a better future. He has diverse entrepreneurial and executive leadership experience in venture-backed, publicly listed and mission-led high growth technology, training and consulting organisations. He raised venture funding as well as built several businesses from cashflow. He has been founding Commercial Director at the Open Data Institute in 2012 and is delighted to have returned to support the leadership and team amidst an exciting new phase of growth in 2020.

Dr Mira Doig

Mira Doig, Ph.D., Technical Director at ABS Laboratories, Ltd.
Mira has over 30 years of experience performing regulated bioanalysis of drugs, metabolites, and biomarkers using GC-MS & LC-MS/MS, and has supported multiple drug development programs from discovery to MAA/NDA submission. In 1997 she established ABS Laboratories as a GLP/GCP accredited bioanalytical contract research organization, which was acquired by ACM Global Labs in 2018. Today, she continues to oversee ACM’s bioanalysis laboratory services and maintains technical and operational excellence.